FacebookTwitterRedditEmail

Big Pharma’s Profiteers: You Want Us to Pay What for These Meds?

It is no secret that the pill profit party is over for drug companies. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular, Concerta, Cymbalta and Abilify have gone off patent and Wall Street is moving on to industries that offer better returns.

To combat investor disenchantment, drug companies have rolled out expensive drugs that treat such rare conditions,  they almost sound like satire. If you are sleepy during the day, you may have narcolepsy says Jazz Pharmaceuticals which its drug Xyrem treats for $35,000 per year.  If you have frequent diarrhea, gas and bloating, you may have exocrine pancreatic insufficiency says AbbVie to sell the drug Creon.

Drug makers are even not above scaring the populace if it sells drugs for rare diseases. Your back pain may not be from working out at all but from a disease called ankylosing spondylitis, says AbbVie, a condition that can be treated with its biologic drug Humira for as much as $20,000 a year. (Injectable “biologic” drugs are a new drug industry push because they are so expensive and less susceptible to generic competition than pills.)

The drug industry is also trying to stay a Wall Street darling with new, uber priced drugs—notably hepatitis C drugs. Gilead Sciences sold $12.4 billion worth of Sovaldi at $1000 a pill last year, reports the New York Timesstraining the budgets of insurance companies and Medicaid programs.”

While drug company representatives initially tried to cast the outrageous prices as recouping martharosenbergtheir research and development costs they quickly back pedaled into admitting the drugs are priced on “value”—what they are “worth” for the patient’s health. Needless to say such valuations come pretty close to the definition of extortion—or offers you “can’t refuse.”

Even business writers cry foul. Why does the same hepatitis C drug that costs $84,000 a year in the US cost $900 a year in Egypt asked Forbes staff writer Avik Roy. Since most hepatitis C patients in the US are uninsured, underinsured or imprisoned, taxpayers pick up the bill through Medicaid, the VA and prison systems writes Roy.

Now Sanofi and Regeneron Pharmaceuticals are rolling out a cholesterol lowering drug which could be embraced by the millions who made the statin Lipitor the best selling drug in the world before it went off patent. Yet the list price of Praluent, an injectable biologic, is over $14,600 a year.  Like Gilead, Sanofi and Regeneron say the price reflects what it is worth in potential benefits to patients and savings to the health care system—e.g. what they can get.

Nor is cost the only question with the new cholesterol drug. Increasingly, high bad cholesterol is viewed as a weak cardiovascular risk factor versus other factors like inflammation. Cholesterol lowering drugs can also be used to duck important lifestyle changes. “Plenty of adults down statins regularly and shine off healthy eating because they know a cheeseburger and steak can’t fool a statin,” writes Dr. Michael J. Breus on the Huffington Post.

Luckily, lawmakers are demanding cost breakdowns from drug companies on the new four-digit priced drugs.  How much are true costs and what is profiteering? Some states are drafting bills that would allow insurers to refuse to pay for a drug if the manufacturer did not file the required cost breakdown reports.

What is the response of drug makers to bills addressing expensive drugs?  They would be costly to comply with, they say.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
January 21, 2020
Sheldon Richman
Warmonger Cotton Accuses Antiwar Think Tank of Anti-Semitism
John Feffer
Trump Makes Space Great Again
Patrick Cockburn
The US and Iran’s Perpetual Almost-War is Unsustainable – and Will End Badly
James C. Nelson
Another Date That Will Live in Infamy: 10 Years After Citizens United
Robert Fisk
Iran Will be Changed Forever by Admitting Its Great Mistake, Unlike the West Which Ignores Its Own Misdeeds
Dean Baker
Did Shareholders’ Benefit by Paying Boeing’s Fired CEO $62 Million?
Susan Roberts
The Demise of the Labour Party and the Future For UK Socialism
Binoy Kampmark
Janus-Faced on Climate Change: Microsoft’s Carbon Vision
David Levin
The Teamster Revolt Against the Hoffa Era
Victor Grossman
Defender and Spearheads
Russell Mokhiber
BS Public Editor and the Disease of Contempt
Tiffany Muller
Get the Money Out of Politics: 10 Years After Citizens United
Laura Flanders
Iowa is Not the Twitterverse
Graham Peebles
Education: Expanding Purpose
Elliot Sperber
Handball in Brooklyn 
January 20, 2020
Paul Street
Trump Showed Us Who He Was Before He Became President
Eric Mann
Martin Luther King and the Black Revolutionary Tradition
Ipek S. Burnett
MLK and the Ghost of an Untrue Dream
Mark Harris
Better Living Through Glyphosate? Spray Now, Ask Questions Later
Katie Fite
Owyhee Initiative Wilderness and Public Lands Deal Critique: Ten Years After
Thomas Knapp
A Loophole for the Lawless: “Qualified Immunity” Must Go
REZA FIYOUZAT
Best Enemies Forever: The Iran-U.S. Kabuki Show
Jeff Mackler
Worldwide Furor Sparked by U.S. Assassination of Iran’s General Suleimani
William deBuys
The Humanitarian and Environmental Disaster of Trump’s Border Wall
Binoy Kampmark
A Matter of Quality: Air Pollution, Tennis and Sporting Officialdom
James Haught
GOP Albatross
Jill Richardson
Why Do We Have School Lunch Debt at All?
Robert Koehler
Nuclear Hubris
Patrick T. Hiller
Instead of Real-Time Commentary, Eight Common-Sense Reason for Not Going to War with Iran
Charles Andrews
A Note on Carlos Ghosn and Global Capitalism
Jeffrey St. Clair
Some Trees: Los Angeles
Weekend Edition
January 17, 2020
Friday - Sunday
Jeffrey St. Clair
Roaming Charges: No Woman, No Cry
Kathleen Wallace
Hijacking the Struggles of Others, Elizabeth Warren Style
Robert Hunziker
The Rumbling Methane Enigma
Frank Joyce
Will the Constitution Fail Again?
Andrew Levine
Biden Daze
Pete Dolack
Claims that the ‘NAFTA 2’ Agreement is Better are a Macabre Joke
Vijay Prashad
Not an Inch: Indian Students Stand Against the Far Right
Ramzy Baroud
Sealed Off and Forgotten: What You Should Know about Israel’s ‘Firing Zones’ in the West Bank
Norman Solomon
Not Bernie, Us. Not Warren, Us. Their Clash Underscores the Need for Grassroots Wisdom
Ted Rall
America’s Long History of Meddling in Russia
David Rosen
The Irregulators vs. FCC: the Trial Begins
Jennifer Matsui
The Krown
Joseph Natoli
Resolutions and Obstacles/2020
Sarah Anderson
War Profiteering is Real
FacebookTwitterRedditEmail